Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Leukemia, Lymphoma, Bone Marrow Failure, Immunodeficiencies, Histiocytosis, Sickle Cell Disease, Beta Thalassemia, Inborn Errors of Metabolism
Interventions: Full Intensity with TBI, Full Intensity, Reduced Intensity, Reduced Intensity (Fanconi); Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Sickle Cell Disease
Interventions: L-citrulline tablets, 1000 mg; Drug
Lead sponsor: Angiogenix; Industry
Eligibility: 10 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Kidney Injury
Interventions: SCD; Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: Chest Pain, Sickle Cell Anemia
Interventions: Nitric Oxide, Nitroglycerin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Sudden Cardiac Death, Ventricular Arrhythmia, Implantable Cardioverter Defibrillator (ICD), Beta-blocker Therapy, Cardiomyopathy
Interventions: Metoprolol Succinate, Carvedilol; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Scottsdale, Arizona • Rome, Georgia • Shawnee Mission, Kansas + 9 more

Conditions: Sickle Cell Disease, Pharmacokinetics
Interventions: L-glutamine; Drug
Lead sponsor: Emmaus Medical, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Disease
Interventions: Lexiscan; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Sickle Cell Disease, Kidney Diseases, Chronic
Interventions: Biospecimen/DNA collection and analysis; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee

Conditions: Sickle Cell Disease
Interventions: Collaborative Care Model, Promoting Resilience in Stress Management; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Chronic Pain
Interventions: Music Therapy; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions: hyperbaric oxygen therapy; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cardiomyopathy, Dilated, Arrhythmia, Anger, Stress
Interventions: Cognitive Behavioral Stress Management (CBSM), Patient Education; Behavioral · Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Subjective Cognitive Decline
Interventions: Mecamylamine Challenge, Placebo Comparator Challenge; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Myocardial Infarction, Death, Sudden, Cardiac
Interventions: Omega-3 Fatty Acids (Fish Oil Supplements), Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 13 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more

Conditions: Sickle Cell Disease
Interventions: Voxelotor Only Product in Oral Dose Form, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease, Thalassemia, Marrow Aplasia
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions: Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 28
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more

Conditions: Sickle Cell Disease
Interventions: WEB-MAP Educational Control Group, WEB-MAP CBT; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 11 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Sickle Cell Crisis
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Hemoglobinopathy, Sickle Cell Disease
Interventions: Long-Term Follow-up Study of patients who received BEAM-101; Drug
Lead sponsor: Beam Therapeutics Inc.; Industry
Eligibility: 14 Years to 37 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2043
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 13 more

Conditions: Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Interventions: Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anemia, Sickle Cell
Interventions: NP Battery, MRI; Behavioral · Procedure
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years to 55 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Hollywood, Florida + 8 more

Conditions: Sudden Cardiac Death
Interventions: Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Birmingham, Alabama • Santa Monica, California

Search by objective public record fields.

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS)

Hyperbaric Oxygen Therapy in Sickle Cell Pain

Mental Stress Reduction in Defibrillator Patients

Attentional Mechanisms in SCD

Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Voxelotor Neurocognitive Function Study

Genes Influencing Iron Overload State

Stroke With Transfusions Changing to Hydroxyurea

Web-MAP Intervention for Youth With Sickle Cell Disease

Low Dose Ketamine and Acute Pain Crisis

A Long-term Follow-up Study in Patients Who Received BEAM-101

A Blood Stem Cell Transplant for Sickle Cell Disease

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease

POWER (Pulse Width Optimized Waveform Evaluation Trial)